Ovarian cancer differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Fahimeh Shojaei (talk | contribs)
No edit summary
Fahimeh Shojaei (talk | contribs)
No edit summary
Line 10: Line 10:
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
|- style="background: #4479BA; color: #FFFFFF; text-align: center;"
! colspan="2" rowspan="4" |Diseases
! colspan="2" rowspan="4" |Diseases
| colspan="7" |'''Clinical manifestations'''
| colspan="6" |'''Clinical manifestations'''
! colspan="4" rowspan="2" |Para-clinical findings
! colspan="4" rowspan="2" |Para-clinical findings
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard'''
Line 17: Line 17:
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Age of onset'''
| rowspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Age of onset'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
| colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Symptoms'''
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination
! colspan="2" rowspan="2" |Physical examination
|-
|-
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings
Line 26: Line 26:
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |vaginal bleeding/discharge
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |vaginal bleeding/discharge
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI dysturbance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |GI dysturbance
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Pleural effusion'''
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Fever'''  
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Fever'''  
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Tenderness
Line 32: Line 31:
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |MRI
|-
|-
! colspan="15" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Gynecologic
! colspan="14" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Gynecologic
|-
|-
| rowspan="14" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovary|Ovarian]]
| rowspan="14" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Ovary|Ovarian]]
Line 39: Line 38:
* Women in reproductive age (15 -45 y/o)
* Women in reproductive age (15 -45 y/o)
| style="background: #F5F5F5; padding: 5px;" | +/–
| style="background: #F5F5F5; padding: 5px;" | +/–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
Line 60: Line 58:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Women in reproductive age (15 -45 y/o)
* Women in reproductive age (15 -45 y/o)
| style="background: #F5F5F5; padding: 5px;" |+/–
| style="background: #F5F5F5; padding: 5px;" | +/–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" |–
| style="background: #F5F5F5; padding: 5px;" | +/–
| style="background: #F5F5F5; padding: 5px;" |+/–
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Depends on the underlying etiology
* Depends on the underlying etiology
Line 82: Line 79:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* >55 y/o
* >55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 100: Line 96:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* >55 y/o
* >55 y/o
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
Line 120: Line 115:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 146: Line 140:
* 10-30 y/o
* 10-30 y/o
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 174: Line 167:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 197: Line 189:
* Male infants
* Male infants
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 226: Line 217:
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Line 244: Line 234:
* It may cause Meigs syndrome (ovarian fibroma, ascites, and hydrothorax)
* It may cause Meigs syndrome (ovarian fibroma, ascites, and hydrothorax)
* It may cause ovarian torsion
* It may cause ovarian torsion
* It may cause pleural effusion
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thecoma]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Thecoma]]
Line 251: Line 242:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* Postmenopausal bleeding
* Postmenopausal bleeding
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 280: Line 270:
* Postmenopausal bleeding
* Postmenopausal bleeding
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 301: Line 290:
* 15 to 35 y/o
* 15 to 35 y/o
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 328: Line 316:
* >55 y/o
* >55 y/o
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 353: Line 340:
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Based on underlying malignancy
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Based on underlying malignancy
Based on underlying malignancy
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 373: Line 357:
* Imaging/biopsy
* Imaging/biopsy
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* The most common primary tumor is in colon, stomach, breast, lung, and contralateral ovary.
* The most common primary tumor is in colon, stomach, breast, lung, and contralateral ovary
* Based on underlying malignancy it may cause peural effusion
|-
|-
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fallopian tube|Tubal]]
| rowspan="5" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Fallopian tube|Tubal]]
Line 381: Line 366:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 407: Line 391:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 428: Line 411:
* NA
* NA
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 453: Line 435:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 473: Line 454:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* >60 y/o
* >60 y/o
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 499: Line 479:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* We may see Latzko triad (abdominal pain, vaginal discgarge, pelvic mass)  
* We may see Latzko triad (abdominal pain, vaginal discgarge, pelvic mass)  
* It may cause pleural effusion
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterus|Uterine]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Uterus|Uterine]]
Line 506: Line 487:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
Line 530: Line 510:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
Line 559: Line 538:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 583: Line 561:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 602: Line 579:
* We do not perform [[CT scan]] and [[MRI]] in [[pregnancy]] but We may unintentionally image the [[pregnancy]] with [[CT scan]] and [[MRI]].
* We do not perform [[CT scan]] and [[MRI]] in [[pregnancy]] but We may unintentionally image the [[pregnancy]] with [[CT scan]] and [[MRI]].
|-
|-
! colspan="15" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Non-gynecologic
! colspan="14" style="background: #7d7d7d; color: #FFFFFF; text-align: center;" |Non-gynecologic
|-
|-
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GIT]]
| rowspan="4" style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Gastrointestinal tract|GIT]]
Line 610: Line 587:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Line 630: Line 606:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* The most common [[complication]] of [[acute appendicitis]]
* The most common [[complication]] of [[acute appendicitis]]
* It may cause pleural effusion
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix cancer|Appendiceal  neoplasm]]<ref name="WHO">Chapter 5: Tumours of the Appendix - IARC. https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/bb2-chap5.pdf Accessed on January 15, 2019</ref>
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Appendix cancer|Appendiceal  neoplasm]]<ref name="WHO">Chapter 5: Tumours of the Appendix - IARC. https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/bb2-chap5.pdf Accessed on January 15, 2019</ref>
Line 637: Line 614:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
Line 668: Line 644:
** [[HNPCC]]
** [[HNPCC]]
** [[Smoking]]
** [[Smoking]]
* It may cause pleural effusion
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Diverticular abscess]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Diverticular abscess]]
Line 674: Line 651:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Line 692: Line 668:
| style="background: #F5F5F5; padding: 5px;" |
| style="background: #F5F5F5; padding: 5px;" |
* [[Diverticular abscess]] happens in almost 30-40% of patients with [[diverticulitis]]  
* [[Diverticular abscess]] happens in almost 30-40% of patients with [[diverticulitis]]  
* It may cause pleural effusion
|-
|-
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Colorectal cancer]]
| style="background: #DCDCDC; padding: 5px; text-align: center;" |[[Colorectal cancer]]
Line 699: Line 676:
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | –
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +/–
Line 729: Line 704:
In case of sever [[hydronephrosis]] or [[renal stone]] we may have [[pelvic]] [[pain]]
In case of sever [[hydronephrosis]] or [[renal stone]] we may have [[pelvic]] [[pain]]
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
Line 756: Line 730:
* ≥65 y/o
* ≥65 y/o
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
Line 787: Line 760:
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" |–
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" | +
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−
| style="background: #F5F5F5; padding: 5px; text-align: center;" |−

Revision as of 14:24, 11 February 2019

Ovarian cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classifications

Pathophysiology

Causes of Ovarian cancer

Differentiating Ovarian cancer from other Diseases

Epidemiology & Demographics

Risk Factors

Screening

Natural History, Complications & Prognosis

Diagnosis

History & Symptoms

Physical Examination

Staging

Laboratory Findings

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Ovarian cancer differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Ovarian cancer differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Ovarian cancer differential diagnosis

CDC on Ovarian cancer differential diagnosis

Ovarian cancer differential diagnosis in the news

Blogs on Ovarian cancer differential diagnosis

Directions to Hospitals Treating Ovarian cancer

Risk calculators and risk factors for Ovarian cancer differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.

Overview

Differentiating [Disease name] from other Diseases

Diseases Clinical manifestations Para-clinical findings Gold standard Additional findings
Age of onset Symptoms Physical examination
Lab Findings Imaging Immunohistopathology
pelvic/abdominal pain or pressure vaginal bleeding/discharge GI dysturbance Fever Tenderness CT scan/US MRI
Gynecologic
Ovarian Follicular cysts
  • Women in reproductive age (15 -45 y/o)
+/– +/–
  • High level of estrogen +/–
  • In US we may see a >3 cm simple cyst with no internal echo and with posterior acoustic enhancement
  • simple cyst with no internal echo or septa
  • NA
  • History/imaging
  • It is associated with hyperestrogenism and endometrial hyperplasia
Theca lutein cysts
  • Women in reproductive age (15 -45 y/o)
+/– +/–
  • Depends on the underlying etiology
  • In US we may see bilaterally enlarged ovaries with multiple cysts
  • Multiple bilateral cysts
  • theca interna cell Hyperplasia
  • History/imaging
  • It is associated with hydatidiform moles, choriocarcinoma, diabetes mellitus and clomiphene intake (ovulation induction)
Serous cystadenoma/carcinoma
  • >55 y/o
  • Bilateral
  • Most common ovarian neoplasm
Mucinous cystadenoma/carcinoma
  • >55 y/o
  • It may cause pseudomyxoma peritonei
Endometrioma
  • Women in reproductive age (15 -45 y/o)
+ + +/– +
  • hyperintensity on T1-weighted images and a hypointensity on T2-weighted images
  • Powder burn hemorrhages
  • Chocolate cyst
  • Laprascopy
  • It may cause infertility
Teratoma
  • 10-30 y/o
+/– +/–
  • High level of HCG and LDH
  • In US we may see cystic adnexal mass with mural components and echogenic lesion due to calcification
  • The iceberg sign
  • Dot-dash pattern
  • We may see evidence of fat components
  • All three germ layers cell
  • Biopsy
  • It may cause ovarian torsion
  • May content thyroid tissue and cause hyperthyroidism
  • In plane radiography we may see calcification due to the presence of tooth in the tumor
Dysgerminoma
  • in the second to third decade of life
+ +/– +/–
  • High level of HCG and LDH
  • Hypercalcemia
  • Multilobulated solid masses
  • We may see ovarian mass with septation which are hyperintense on T1 and hypo or isointense on T2 imaging
  • Sheets fried egg appearance cells
  • Biopsy
  • Same as male seminomas
Yolk sac tumor
  • Young children
  • Male infants
+ +
  • High levels of AFP
  • In US we may see a combination of echogenic and hypoechoic components
  • Ovarian mass with hemorrhagic areas
  • Yellow appearance
  • Hemorrhagic
  • Schiller-Duval bodies (glomeruli like structures)
  • Biopsy
  • The other name is ovarian endodermal sinus tumor
Fibroma
  • >50 y/o
  • Pulling sensation in the groin
+/–
  • High levels of CA-125
  • In CT scan we may see a unilateral mass with poor contrast enhancement
  • Low signal intensity on T1 and T2
  • We may see scattered hyperintense areas due to edema or cystic degeneration
  • Spindle-shaped fibroblast
  • Biopsy
  • It may cause Meigs syndrome (ovarian fibroma, ascites, and hydrothorax)
  • It may cause ovarian torsion
  • It may cause pleural effusion
Thecoma
  • >50 y/o
+/–
  • Postmenopausal bleeding
  • High level of estrogen
  • In US we may see non-specific ovarian mass
  • We may see evidence of endometrial hyperplasia due to increased level of estrogen
  • Hyperintense on T2
  • T1 intensity depends on the amount of fibrous tissue (fibrous tissue lead to hypointensity)
  • Lipid-laden stromal cells with pale, vaculolated cytoplasm
  • Biopsy
  • We may see endometrial cancer as e result of hyper-estrogenism
  • We may see ovarian fibrothecoma (mixture of fibroma and thecoma)
Granulosa cell tumor
  • 50-60 y/o
+
  • Postmenopausal bleeding
+/–
  • High level of estrogen and progestron
  • We may see inhibin, calretinin, and Ki-67 on the surface of granulosa cell tumor cells
  • In US we may see solid, cystic, or multiloculated solid and cystic mass
  • We may see solid, cystic, or multiloculated solid and cystic mass
  • Call-Exner bodies
  • Biopsy
  • In postmenopausal women may cause breast tenderness
Sertoli-leydig cell tumor
  • 15 to 35 y/o
+/–
  • In US we may see unilateral Well-defined hypoechoic lesion
  • Low T2 signal intensity
  • areas of high signal intensity
  • Lydig cells (Polygonal pink cells with eosinophilic cytoplasm
  • Sertoli cells (clear vacuolated cytoplasm)
  • Biopsy
Brenner tumor
  • >55 y/o
+/–
  • In US we may see hypoechoic solid mass and calcification
  • Hypointense on T2 because of fibrous content
  • Yellow/pale appearance
  • Transitional cell tumor (resembles bladder)
  • Coffee bean nuclei on H&E
  • Biopsy
  • Most of the times it's an accidental finding
Krukenberg tumor
  • >55 y/o
+/– +/–

Based on underlying malignancy

  • In case of metastatic GI cancers we may see iron deficiency anemia
  • Mostly bilateral, complex ovarian lesion
  • In CT scan we may see evidence of concurrent malignancy in other organs
  • Mostly bilateral, complex ovarian lesion with solid components
  • Internal hyperintensity on T1 and T2 weighted MR images because of mucin
  • Evidence of concurrent malignancy in other organs
  • Mucin-secreting signet cell
  • Imaging/biopsy
  • The most common primary tumor is in colon, stomach, breast, lung, and contralateral ovary
  • Based on underlying malignancy it may cause peural effusion
Tubal tubo-ovarian abscess
  • Young women (15-30 y/o
+ + + +
  • High levels of inflammatory markers
  • Leukocytosis
  • In US we may see multilocular complex lesion mostly bilateral with debry inside
  • We may see a pelvic mass filled with fluid with thick walls
  • hypointense in T1 and heterogeneous in T2
  • In abscess aspiration we may see anaerobic organisms
  • History/imaging
  • The most common risk factors are previous PID, diabetes mellitus, intrauterine device and history of uterine surgery
Ectopic pregnancy
  • Women in reproductive age (15 -45 y/o)
+ + +/– +
  • High level of BhCG
  • Progesterone level ≤5 ng/ml
  • In US we may see empty uterine cavity, tubal ring sign, ring of fire sign (Doppler), extra-uterine fetal heart rate
  • NA
  • NA
  • History/imaging
  • Any women in reproductive age presenting with abdominal pain or amenorrhea should be screened for ectopic pregnancy
Hydrosalpinx
  • NA
+ +/–
  • In US we may see tubal longitudinal folds thickening (cogwheel appearance)
  • In CT scan we may see tubular adnexal lesion with fluid attenuation
  • Dilated Fallopian tube with fluid signal intensity
  • NA
  • Imaging
  • It is associated with endometriosis (haematosalpinx), ovulation induction, pelvic inflammatory disease, post-hysterectomy, tubal ligation, and tubal malignancy
  • It may cause infertility
Salpingitis
  • Women of reproductive age
+ + + +
  • Leukocytosis
  • In US we may see , edematous and thickened endosalpingeal folds
  • NA
  • NA
  • History/physical exam
  • It may cause infertility
Fallopian tube carcinoma
  • >60 y/o
+ + + +/–
  • High levels of CA125
  • US findings are non specific (complex mass on Fallopian tube
  • We may see papillary projections
  • Low signal on T1
  • In case of hemorrhage inside the tumor we may see high signal intensity on T1
  • Low or of intermediate signal on T2
  • In case of serous fluid inside the tumor we may see high signal intensity on T2
  • Based on the tumor type we may have different biopsy finding
  • Biopsy
  • We may see Latzko triad (abdominal pain, vaginal discgarge, pelvic mass)
  • It may cause pleural effusion
Uterine Leiomyoma
  • Women of reproductive age
+ + +/–
  • In chronic cases, we may see mild anemia
  • In US we may see hypoechoic mass with calcification and cystic areas of necrosis or degeneration may
  • Low to intermediate signal intensity on T1 and T2
  • In case of necrosis inside the mass, there might be some high signal lesions on T2
  • Smooth muscle
  • Imaging
  • It may cause infertility
Choriocarcinoma
  • Women in reproductive age (15 -45 y/o)
+ + +/– +
  • High level of B-hCG
  • In US we may see heterogeneous mass infiltrating myometrium
  • Enlarged uterus
  • Necrosis +
  • Hemorrhage +
  • In CT scan we may see evidence of metastasis to brain, lung and other organs
  • We may see an infiltrative uterine mass and thickening of uterine wall
  • Trophoblastic tissue origin
  • columns and sheets of trophoblastic tissue invading uterine muscle and blood vessels
  • Biopsy
  • It is associated with bilateral Theca lutein cysts
  • Cannonball metastases to the lungs
  • May cause hemoptysis
  • We may see passing of grapes like tissue from the vagina
Leiomyosarcoma
  • >55 y/o
+ + +/–
  • Increased uterine size
  • Irregular central zones of low signal intensity (tumor necrosis)
Pregnancy +/− +/− +/−
  • NA
Non-gynecologic
GIT Appendiceal abscess
  • NA
+ + +/– +
  • NA
Appendiceal neoplasm[1] + + +/–
  • Soft tissue mass in the appendix
  • We may see invasion to other structures
  • Gray/yellowi color
  • Cystic structures with angiolymphatic invasion
Diverticular abscess
  • >50 y/o
+ + +/– +
  • Ill-defined lesion with air and fluid inside
  • Adjacent bowel loop wall thickening
  • Smudged mesenteric fat
  • We may see a lesion with air and fluid inside
  • NA
Colorectal cancer
  • >50 y/o
+ + +/–
  • We may see tumor mass and the extension of tumor to other structures
Renal

Bladder

Pelvic kidney
  • NA
−/+

In case of sever hydronephrosis or renal stone we may have pelvic pain

  • We may see normal kidney structure
  • NA
  • It may cause tract infection (UTI), obstruction, and renal calculi.
  • It may be associated with RCC
Bladder cancer
  • ≥65 y/o
+
  • isointense compared to muscle in T!
  • slightly hyperintense compared to muscle in T2
Others Retroperitoneal sarcoma[2]
  • 40-50 y/o
+ +

check sites of cancer that may metastasize to the ovaries (eg, stomach, colorectal, breast)

check rectum, liver, spleen, lungs, inguinal or supraclavicular lymph nodes for ovary metastase

  • Bladder tumour–associated antigen (BTA)
  • Nuclear matrix proteins (NMP)
  • Mucin and carcinoembryonic antigen (CEA)

References

  1. Chapter 5: Tumours of the Appendix - IARC. https://www.iarc.fr/en/publications/pdfs-online/pat-gen/bb2/bb2-chap5.pdf Accessed on January 15, 2019
  2. Storm FK, Mahvi DM (July 1991). "Diagnosis and management of retroperitoneal soft-tissue sarcoma". Ann. Surg. 214 (1): 2–10. PMC 1358407. PMID 2064467.

Template:WH Template:WS